Literature DB >> 32637647

Effect of haemoglobin levels on outcome in intravenous thrombolysis-treated stroke patients.

Valerian L Altersberger1, Lars Kellert2,3, Abdulaziz S Al Sultan4, Nicolas Martinez-Majander5, Christian Hametner3, Ashraf Eskandari6, Mirjam R Heldner7, Sophie A van den Berg8, Andrea Zini9, Visnja Padjen10, Georg Kägi11, Alessandro Pezzini12, Alexandros Polymeris1, Gian M DeMarchis1, Marjaana Tiainen5, Silja Räty5, Stefania Nannoni6, Simon Jung7, Thomas P Zonneveld8, Stefania Maffei9, Leo Bonati1, Philippe Lyrer1, Gerli Sibolt5, Peter A Ringleb3, Marcel Arnold7, Patrik Michel6, Sami Curtze5, Paul J Nederkoorn8, Stefan T Engelter1,13, Henrik Gensicke1,13.   

Abstract

INTRODUCTION: Alterations in haemoglobin levels are frequent in stroke patients. The prognostic meaning of anaemia and polyglobulia on outcomes in patients treated with intravenous thrombolysis is ambiguous. PATIENTS AND METHODS: In this prospective multicentre, intravenous thrombolysis register-based study, we compared haemoglobin levels on hospital admission with three-month poor outcome (modified Rankin Scale 3-6), mortality and symptomatic intracranial haemorrhage (European Cooperative Acute Stroke Study II-criteria (ECASS-II-criteria)). Haemoglobin level was used as continuous and categorical variable distinguishing anaemia (female: <12 g/dl; male: <13 g/dl) and polyglobulia (female: >15.5 g/dl; male: >17 g/dl). Anaemia was subdivided into mild and moderate/severe (female/male: <11 g/dl). Normal haemoglobin level (female: 12.0-15.5 g/dl, male: 13.0-17.0 g/dl) served as reference group. Unadjusted and adjusted odds ratios with 95% confidence intervals were calculated with logistic regression models.
RESULTS: Among 6866 intravenous thrombolysis-treated stroke patients, 5448 (79.3%) had normal haemoglobin level, 1232 (17.9%) anaemia - of those 903 (13.2%) had mild and 329 (4.8%) moderate/severe anaemia - and 186 (2.7%) polyglobulia. Anaemia was associated with poor outcome (ORadjusted 1.25 (1.05-1.48)) and mortality (ORadjusted 1.58 (1.27-1.95)). In anaemia subgroups, both mild and moderate/severe anaemia independently predicted poor outcome (ORadjusted 1.29 (1.07-1.55) and 1.48 (1.09-2.02)) and mortality (ORadjusted 1.45 (1.15-1.84) and ORadjusted 2.00 (1.46-2.75)). Each haemoglobin level decrease by 1 g/dl independently increased the risk of poor outcome (ORadjusted 1.07 (1.02-1.11)) and mortality (ORadjusted 1.08 (1.02-1.15)). Anaemia was not associated with occurrence of symptomatic intracranial haemorrhage. Polyglobulia did not change any outcome. DISCUSSION: The more severe the anaemia, the higher the probability of poor outcome and death. Severe anaemia might be a target for interventions in hyperacute stroke.
CONCLUSION: Anaemia on admission, but not polyglobulia, is a strong and independent predictor of poor outcome and mortality in intravenous thrombolysis-treated stroke patients. © European Stroke Organisation 2019.

Entities:  

Keywords:  Anaemia; haemoglobin; intravenous thrombolysis; outcome; polyglobulia; stroke

Year:  2019        PMID: 32637647      PMCID: PMC7313367          DOI: 10.1177/2396987319889468

Source DB:  PubMed          Journal:  Eur Stroke J        ISSN: 2396-9873


  39 in total

1.  Bleeding and subsequent anemia: a precipitant for cerebral infarction.

Authors:  J S Kim; S Y Kang
Journal:  Eur Neurol       Date:  2000       Impact factor: 1.710

2.  Effect of haemoglobin concentration on brain oxygenation in focal stroke: a mathematical modelling study.

Authors:  F Dexter; B J Hindman
Journal:  Br J Anaesth       Date:  1997-09       Impact factor: 9.166

3.  IV thrombolysis and statins.

Authors:  S T Engelter; L Soinne; P Ringleb; H Sarikaya; R Bordet; J Berrouschot; C Odier; M Arnold; G A Ford; A Pezzini; A Zini; K Rantanen; A Rocco; L H Bonati; L Kellert; D Strbian; A Stoll; N Meier; P Michel; R W Baumgartner; D Leys; T Tatlisumak; P A Lyrer
Journal:  Neurology       Date:  2011-08-17       Impact factor: 9.910

4.  Anemia in young patients with ischaemic stroke.

Authors:  L Kellert; M Kloss; A Pezzini; T M Metso; A J Metso; S Debette; D Leys; V Caso; V Thijs; A Bersano; E Touzé; T Tatlisumak; H Gensicke; P A Lyrer; J Bösel; S T Engelter; C Grond-Ginsbach
Journal:  Eur J Neurol       Date:  2015-02-24       Impact factor: 6.089

5.  Liberal versus restrictive transfusion thresholds for patients with symptomatic coronary artery disease.

Authors:  Jeffrey L Carson; Maria Mori Brooks; J Dawn Abbott; Bernard Chaitman; Sheryl F Kelsey; Darrell J Triulzi; Vankeepuram Srinivas; Mark A Menegus; Oscar C Marroquin; Sunil V Rao; Helaine Noveck; Elizabeth Passano; Regina M Hardison; Thomas Smitherman; Tudor Vagaonescu; Neil J Wimmer; David O Williams
Journal:  Am Heart J       Date:  2013-04-08       Impact factor: 4.749

6.  Sex differences and hemoglobin levels in relation to stroke outcomes.

Authors:  W Taylor Kimberly; Fabricio O Lima; Sydney O'Connor; Karen L Furie
Journal:  Neurology       Date:  2013-01-30       Impact factor: 9.910

7.  Fluid shear stress modulates surface expression of adhesion molecules by endothelial cells.

Authors:  M Morigi; C Zoja; M Figliuzzi; M Foppolo; G Micheletti; M Bontempelli; M Saronni; G Remuzzi; A Remuzzi
Journal:  Blood       Date:  1995-04-01       Impact factor: 22.113

Review 8.  Blood transfusion after percutaneous coronary intervention and risk of subsequent adverse outcomes: a systematic review and meta-analysis.

Authors:  Chun Shing Kwok; Matthew W Sherwood; Sarah M Watson; Samina B Nasir; Matt Sperrin; Jim Nolan; Tim Kinnaird; Songsak Kiatchoosakun; Peter F Ludman; Mark A de Belder; Sunil V Rao; Mamas A Mamas
Journal:  JACC Cardiovasc Interv       Date:  2015-02-18       Impact factor: 11.195

9.  Red blood cell transfusion in patients with ST-elevation myocardial infarction-a meta-analysis of more than 21,000 patients.

Authors:  R I Mincu; T Rassaf; M Totzeck
Journal:  Neth Heart J       Date:  2018-09       Impact factor: 2.380

10.  Association of anemia and hemoglobin decrease during acute stroke treatment with infarct growth and clinical outcome.

Authors:  Sebastian Bellwald; Rupashani Balasubramaniam; Michael Nagler; Meret S Burri; Samuel D A Fischer; Arsany Hakim; Tomas Dobrocky; Yannan Yu; Fabien Scalzo; Mirjam R Heldner; Roland Wiest; Marie-Luise Mono; Hakan Sarikya; Marwan El-Koussy; Pasquale Mordasini; Urs Fischer; Gerhard Schroth; Jan Gralla; Heinrich P Mattle; Marcel Arnold; David Liebeskind; Simon Jung
Journal:  PLoS One       Date:  2018-09-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.